9
Nov
2023
Vor Bio Shows CRISPR’d Stem Cell Transplants Take Hold in AML Patients, Enable ADCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Nov
2023
Architects and Gardeners, a Captivating Developmental Biology Book, & an Inspiring Immigrant Story
Architects and Gardeners Most leadership offsites I’ve attended have included some flavor of personality assessment – not so much to formally classify us, but rather to make the point that different people have different styles, and to emphasize that you can’t assume everyone you work with approaches the world the same way you do. In this spirit, I wanted to... Read More
7
Nov
2023
Kynexis Gets €57M to Pursue New Treatment Pathway for Schizophrenia
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2023
Think Clinical Trials Are Working OK? Ask a Cancer Patient
I can’t stop thinking about a recent series of poignant blog posts, written by an emergency room physician affiliated with the Mayo Clinic. Her husband has been battling a terrible cancer – recurrent/metastatic head and neck squamous cell carcinoma. Given what she does for a living, the author, Dr. Bess Stillman, is about as well-positioned to be a savvy patient... Read More
3
Nov
2023
ProfoundBio, Challenging ImmunoGen, Delivers Responses in First Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2023
Lilly Doubles Down on Base Editing, BioMarin CEO Exits, and Layoffs Mount
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Nov
2023
Investing in the Future of Medicine: Reid Huber on The Long Run
Today’s guest on the The Long Run is Reid Huber. He’s a partner at Third Rock Ventures in Boston. Third Rock is known in biotech as one of the venture firms that creates new companies that seek to turn groundbreaking science into new medicines. Since its founding in 2007, Third Rock has put together a portfolio of 62 companies that... Read More
1
Nov
2023
Gate Bioscience, Backed by Versant, A16Z, Arch, Gets $60M to Block Protein Secretion
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2023
Nimbus HPK1 Inhibitor Activates Immune System Against Tumors in Early Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2023
How The Unmet Needs of Patients Made Me A (Grounded) BioTechno-Optimist
My Ground Truth Every other week, I stroll across the Longfellow Bridge from Cambridge to Boston. It can be a magnificent walk in the fall and spring, when the weather is temperate and the skies clear. You can see the deep blue of the Charles River, the Esplanade on your left, with the Boston skyline behind it, and the Citgo... Read More
26
Oct
2023
Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2023
Aiolos Bio, With $245M from Atlas, Bain, Aims at TSLP for Asthma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Oct
2023
Thermo’s $3.1B Proteomics Bet, UCB’s Rare Two-Fer, & More Cutbacks
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2023
Catching Cancer Early, Investing in Data and AI: Jeff Huber on The Long Run
Today’s guest on The Long Run is Jeff Huber. He’s the co-founder and general partner at Triatomic Capital. It’s a relatively new venture fund that seeks to back “century-defining” businesses in Engineered Biology, New Materials, Next Gen Compute, New Energy, & Automated Economy. Jeff and his fellow partners are looking at startups that collect and analyze data to address big... Read More
12
Oct
2023
Another GLP-1 Victory, Bayer Invests in Berkeley, & EU Tells Illumina to Divest
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2023
An mRNA Nobel, Lilly Acquires Point, and Investment in Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2023
Fulfilling the Promise of Sickle Cell Gene Therapy
Two gene therapies for sickle cell disease, CRISPR/Vertex’s exa-cel and Bluebird Bio’s lovo-cel, are being reviewed by the FDA and are likely to win US approval for sale by the end of the year. While it will take more time to fully establish long-term safety and efficacy of these therapies, they offer a glimmer of hope for a cure. This... Read More
3
Oct
2023
Targeted Radiation for Cancer: Lori Lyons-Williams on The Long Run
Today’s guest on The Long Run is Lori Lyons-Williams. She’s the CEO of Menlo Park, Calif. and Vancouver, BC-based Abdera Therapeutics. Abdera is a startup developing targeted antibody drugs loaded with potent microdoses of radiation to give them extra tumor-killing punch. This type of treatment modality has been around for decades. Targeted radiation hasn’t lived up to the full potential... Read More
19
Sep
2023
Turning the Tables: Rob Perez Interviews Me on The Long Run
This episode is unusual. Many listeners know of Rob Perez. He’s an operating partner at General Atlantic, the former CEO of Cubist Pharmaceuticals, and the founder of Life Science Cares. Rob and I have gotten to know each other better the past couple years through our shared passion for mobilizing the biotech community to fight poverty. The Timmerman Traverse for... Read More
11
Sep
2023
Sterile Information: Early Forecasting Not The Answer To R&D Productivity Woes
Two recent Wall Street Journal deep-dives nicely bookend a critical, and unresolved, tension faced by large pharmaceutical companies: how can their R&D organizations discover, develop, and deliver the new medicines patients await, and the growth and return on investment that shareholders demand? Early this year, I discussed an April 2023 profile of Lilly by journalist Peter Loftus, who described how the company, led by a physician-scientist... Read More